CTLT News and Press, Catalent Inc. From 03/24/24

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

2024-03-09 13:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors’ eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated...

2024-03-08 12:10:25 ET More on Novo Nordisk Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy Novo Nordi...

Commits to reducing Scope 1 and 2 greenhouse gas emissions by 42% from its 2022 baseline by 2030, with commitment to ensuring 70% of supplier emissions have science-based targets by end of fiscal 2028. Implemented ISO-certified environmental management systems at 24 locations, which a...

2024-03-05 13:02:26 ET More on Eli Lilly Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Eli Lilly price target upped at UBS on GLP...

2024-03-01 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chord Energy Corporation (NASDAQ: CH...

2024-02-16 08:30:00 ET Summary Novo Nordisk investors have witnessed significant growth and outperformed the S&P 500, but the recent surge has led to considerable overvaluation. The company remains the market leader in the GLP-1 market, benefiting from the surge in demand amid...

2024-02-14 15:01:23 ET More on Catalent Catalent - Novo Holdings Merger: Attractive Spread Catalent: Debt Remains An Overhang FTC likely to look at Catalent alternatives in review of Novo deal - report Catalent Q2 2024 Earnings Preview Seeking Alpha&#...

2024-02-12 08:41:44 ET More on Novo Nordisk Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Booming weight-loss drug market to lift “pick-and-shovel...